FDA approves Retatrutide this year priced at 3.2% on Polymarket, up 1.1 points, on $596K traded

Polymarket traders priced FDA approval of Retatrutide this year at 3.2%, up 1.1 percentage points, in the supplied market snapshot published Oct 28, 2026 · 12:09 PM ET. Total traded volume stood at $596K. The price reflects expectations about approval, not an announcement that approval has occurred.

A higher price, but a low implied probability

The move leaves approval this year a low-probability outcome in the market’s pricing. The increase is measured in percentage points, rather than as a percentage return.

The accompanying news-search summary identified no significant new platform headline in the preceding 30 minutes. The supplied material therefore does not establish a fresh news catalyst for the price change or provide a regulatory update explaining it.

Reading the snapshot

According to predictionbubbles.net, its market data refreshes every 15 minutes, and its movement figures measure probability changes over the preceding 24 hours. The site defines traded volume as total activity where the venue publishes it; the $596K figure should not be read as money traded during the latest move.

PredictionBubbles says it displays prices from Polymarket and Kalshi, where trading is continuous. Its supplied page explains those data conventions but does not include the Retatrutide contract’s wording or resolution criteria, limiting what can be concluded beyond the headline snapshot.

What it means for prediction markets

• Direction and level differ: the probability rose 1.1 percentage points, but the 3.2% price still indicates a low market-implied likelihood of approval this year.
• The catalyst is unconfirmed: the supplied reporting does not connect the repricing to a new FDA development.
• Volume is not timing: $596K represents total traded volume, not evidence of a recent burst of trading.
• Contract details remain important: without the exact wording and resolution rules, the supplied material cannot establish precisely what would qualify as an approval outcome.